This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Graves, D. F Articles by Zwischenberger, J. B Search for Related Content PubMed PubMed Citation Articles by Graves, D. F Articles by Zwischenberger, J. B Social Bookmarking                         What's this?

Anticoagulation practices during neonatal extracorporeal membrane oxygenation: survey results

Extracorporeal Membrane Oxygenation Programme, University of Texas Medical Branch, Galveston, Texas

Jill M Chernin

Extracorporeal Membrane Oxygenation Programme, University of Texas Medical Branch, Galveston, Texas

Mark Kurusz

Extracorporeal Membrane Oxygenation Programme, University of Texas Medical Branch, Galveston, Texas

Joseph B Zwischenberger

Extracorporeal Membrane Oxygenation Programme, University of Texas Medical Branch, Galveston, Texas

To ascertain current anticoagulation management during neonatal extracorporeal membrane oxygenation (ECMO), a telephone survey was undertaken of all active ECMO (n = 81, 100% response rate) centres in the USA. Hospital policies regarding federal regulations governing laboratory tests [Clinical Laboratory Improvement Amendment (CLIA) 1988] were determined along with specific patient anticoagulation strategies and use of specific activated coagulation time (ACT) equipment. More than 90% of the respondents use the Hemochron device (International Technidyne Corp, Edison, NJ, USA) while the remaining centres use the Hemotec device (Medtronic Hemotec, Inc, Englewood, CO, USA). Quality control (QC) testing is performed by most centres, but there is no consensus regarding frequency of testing nor methods for dealing with abnormal results. Nearly one-half of the centres use beef lung-derived heparin and the other half use porcine intestinal-derived heparin. One-half of the programmes had a minimum heparin dose despite the ACT value, but the range varied significantly. Four out of five respondents reported that heparin dosages were dictated strictly by ACT results, and 63% will temporarily stop heparin administration for high ACT results, bleeding and/or surgery. Approximately one-third of the centres perform proficiency testing of the equipment in compliance with CLIA 1988. In conclusion, there appears to be no consensus regarding commitment to a QC programme among active ECMO centres.

Perfusion, Vol. 11, No. 6, 461-466 (1996)
DOI: 10.1177/026765919601100607


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. W. Baird, D. Zurakowski, B. Robinson, S. Gandhi, L. Burdis-Koch, J. Tamblyn, R. Munoz, K. Fortich, and F. A. Pigula Anticoagulation and Pediatric Extracorporeal Membrane Oxygenation: Impact of Activated Clotting Time and Heparin Dose on Survival Ann. Thorac. Surg., March 1, 2007; 83(3): 912 - 920. [Abstract] [Full Text] [PDF]

				B. Stiller, Y. Weng, M. Hubler, J. Lemmer, N. Nagdyman, M. Redlin, P. E. Lange, and R. Hetzer Pneumatic pulsatile ventricular assist devices in children under 1 year of age Eur. J. Cardiothorac. Surg., August 1, 2005; 28(2): 234 - 239. [Abstract] [Full Text] [PDF]

				L. Lequier Extracorporeal Life Support in Pediatric and Neonatal Critical Care: A Review J Intensive Care Med, September 1, 2004; 19(5): 243 - 258. [Abstract] [PDF]

				J A Murphy, C M Savage, S K Alpard, D J Deyo, J B Jayroe, and J B Zwischenberger Low-dose versus high-dose heparinization during arteriovenous carbon dioxide removal Perfusion, December 1, 2001; 16(6): 460 - 468. [Abstract] [PDF]

				T. M. Ambrose, C. A. Parvin, E. Mendeloff, and L. Luchtman-Jones Evaluation of the TAS Analyzer and the Low-Range Heparin Management Test in Patients Undergoing Extracorporeal Membrane Oxygenation Clin. Chem., May 1, 2001; 47(5): 858 - 866. [Abstract] [Full Text] [PDF]

				M. Codispoti and P. S Mankad Management of anticoagulation and its reversal during paediatric cardiopulmonary bypass: a review of current UK practice Perfusion, May 1, 2000; 15(3): 191 - 201. [Abstract] [PDF]